If you have not received your notification, please contact us at wclc2019-abstracts at icsevents.com. The International Association for the Study of Lung Cancer thanks all individuals who have submitted abstracts for the IASLC 2019 World Conference on Lung Cancer. Click here to view the Abstract Submission Guidelines.
Don't forget to register for WCLC 2019
|Abstract Submission Deadline||April 10, 2019 (23:59 PST)|
|Travel Award Application Deadline||April 10, 2019 (23:59 PST)|
|Author Notification of Acceptance Sent||May 24, 2019|
|Travel Award Notifications Sent||June 7, 2019|
|Presenting Author Registration Deadline||July 5, 2019|
|Presenting Author and Abstract Title Changes Deadline||July 5, 2019|
|Late-Breaking Abstract Final Data Submission Deadline||July 19, 2019|
|Late-Breaking Abstract Notifications||July 22, 2019|
|Abstract Titles Release Date||August 2, 2019|
|Oral and Mini Oral Presentation Slide Submission Deadline||August 5, 2019|
|E-Poster Presentation Slide Submission Deadline||August 5, 2019|
|Full Abstracts Release Date||August 21, 2019 (17:00 EDT)|
|Poster Presentation Slide Submission Deadline||August 30, 2019|
The Core Program and Regional Organizing Committee for the IASLC 2019 World Conference on Lung Cancer are inviting the submission of scientific abstracts. Authors are asked to submit abstracts under one of the following categories:
Clinical Trial in Progress
Step 1. Title & Topic
Step 2. Authors
Step 3. Disclosure
ALL abstract authors are expected to disclose to the program audience any/all relevant financial relationships related to the content of their presentation.
IMPORTANT NOTE: Per CME guidelines, industry employees cannot present an abstract if the content of the abstract relates to business lines or products of their employer.
The author must disclose all entities producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with which the author/the author’s spouse/partner have, or have had, a relevant financial relationship within the past 12 months. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
If the author has a relevant financial relationship, please provide the nature of relevant financial relationship as well as the name of company(s).
The author warrants that nothing in their presentation is libelous or will infringe the rights of any third party. The author also warrants that for any third party materials incorporated into their presentation, they have obtained all necessary permission from the copyright owner of such material. Upon request Presenter agrees to furnish copies of said permission(s) to IASLC. The author is responsible for all fees, royalties and other charges for the use of materials. The author shall indemnify IASLC for all damages, costs and expenses, including attorneys’ fees, incurred by IASLC as a result of a violation of this paragraph.
Presentations must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If the CME educational material or content includes trade names, where available trade names from several companies should be used, not just trade names from a single company.
The author must read and agree to the statements above.
The author or an immediate family member of the author in the past ten years received trips, travel, gifts, or other in-kind payments not directly related to research activities, research funding or other funding in an entity having an investment, licensing, or other commercial interest in tobacco or tobacco products.
The author or an immediate family member of the author in the past ten years received research funding, honoraria, gifts etc. from an entity funded directly by an entity having an investment, licensing or other commercial interest in tobacco or tobacco products.
The author must read and agree to the statements above.
Step 4. Abstract Text
Step 5. Preview & Submit
Please carefully review the affiliation of all your co-authors as this is how it will appear in the JTO and as well as the IASLC WCLC 2019 Scientific Program
When will the Peer Review and Late-Breaking abstract titles and abstract body be published online?
Does WCLC accept abstracts that have been submitted and presented to a previous Congress (ie, encore abstracts, trials in progress encore abstracts)?
Are case reports/case series considered for presentations?
What is the withdraw deadline for regular submissions and late breaking submissions?
For late-breaking abstracts, does the congress only permit abstracts that report on Phase 3 [and higher] studies?
Could I send my manuscript to publish to a journal in my country before WCLC?
Is industry allowed to be in lead or senior author positions on the by-line for WCLC abstract submissions?
Does the restriction towards pharmaceutical/commercial authors apply to all abstracts submitted or is it just those accepted for oral and mini oral presentation?
Would it be possible to submit an abstract without results and conclusion?
Is there a limit on the number of abstracts in which an author can be lead author?
Is there any charge for the submission of abstracts, and if so how much is it?
For inquiries, please contact wclc2019-abstracts at icsevents.com. If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.
Venue & City Information
Call for Volunteers
First Time WCLC Attendees
Program at a Glance
Interactive Breakfast Sessions
Information for Abstract Presenters
Call for Abstracts
IASLC International Mentorship Program
Advisory Board and Ancillary Meetings
Keep up to date with Conference News & Alerts.